29 March 2017
Antiva accepts $22m in series C round
Osage University Partners was among the investors in the University of California San Diego spinout's latest round, which will support phase 1 trial for its lead compound.
US-based human papilloma virus (HPV) treatment developer Antiva Biosciences raised $22m in a series C round yesterday featuring spinout-focused venture capital firm Osage University Partners.
Brace Pharma Capital, the strategic investment arm of pharmaceutical company EMS, led the round, which included Alexandria Venture Investments,…Read More.
28 March 2017
Saphlux lights up $5m investment
Saphlux, a LED technology spinout of Yale University, has obtained $5m in funding from a consortium led by Leyard, an outdoor LED display producer, with a $3.5m commitment.
27 March 2017
News round up 27 March 2017
Touchstone Innovations, which co-founded the cellular…